Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Gynecomastia with risperidone-fluoxetine combination.

F Benazzi1

  • 1Department of Psychiatry Public Hospital Morgagni Forli, Italy.

Pharmacopsychiatry
|March 10, 1999
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Prevalence of severe depression in private practice depressed outpatients.

International journal of psychiatry in clinical practice·2014
Same author

Non-reactive mood in outpatient depression: A 557-case study.

International journal of psychiatry in clinical practice·2014
Same author

Citalopram withdrawal symptoms.

European psychiatry : the journal of the Association of European Psychiatrists·2009
Same author

Psychotic depression in private practice outpatients.

European psychiatry : the journal of the Association of European Psychiatrists·2009
Same author

On-line estimation and detection of abnormal substrate concentrations in WWTPs using a software sensor: a benchmark study.

Environmental technology·2007
Same author

Melancholia and atypical depression in the Zurich study: epidemiology, clinical characteristics, course, comorbidity and personality.

Acta psychiatrica Scandinavica. Supplementum·2007
Same journal

A Tribute to Prof. Jules Angst highlighting his Contributions to Clozapine.

Pharmacopsychiatry·2026
Same journal

Correction: Escitalopram and Clonazepam Affect Gasotransmitter-related Enzyme (nNOS, HO-2, CBS) Gene Expression in the Rat Brain.

Pharmacopsychiatry·2026
Same journal

Correction: Non-Response to Antidepressants: Risk Factors and Therapeutic Possibilities.

Pharmacopsychiatry·2026
Same journal

Consensus Guidelines for Therapeutic Drug Monitoring in Neuropsychopharmacology: Update 2026 - Pharmacokinetic, pharmacogenetic and clinical aspects.

Pharmacopsychiatry·2026
Same journal

Therapeutic Drug Monitoring of Cannabinoids: Therapeutic Reference Ranges for Delta-9-tetrahydrocannabinol in Medical Cannabis, Nabiximols, Dronabinol and Nabilone.

Pharmacopsychiatry·2026
Same journal

A Naturalistic Study on the Cost Reduction and Efficacy of Long-acting Antipsychotics in an Early Intervention Programme for Patients with Recent-onset Psychosis.

Pharmacopsychiatry·2026
See all related articles

Gynecomastia, a side effect of antipsychotics, occurred in a patient on low-dose risperidone combined with fluoxetine. This drug interaction, potentially linked to prolactin, has not been previously reported.

Area of Science:

  • Endocrinology
  • Pharmacology
  • Neuroscience

Background:

  • Gynecomastia is a known side effect of neuroleptic antipsychotic medications.
  • This is linked to elevated prolactin levels caused by dopamine D2 receptor blockade.
  • Atypical antipsychotics like risperidone may have a lower incidence, especially at lower doses.

Observation:

  • A patient presented with gynecomastia while on a low dose of risperidone (0.5 mg/day) combined with fluoxetine.
  • The patient had not experienced gynecomastia previously when on a higher dose of risperidone alone (3 mg/day).

Findings:

  • The combination of low-dose risperidone and fluoxetine appears to have induced gynecomastia.
  • This suggests a potential drug interaction between risperidone and fluoxetine.

Related Experiment Videos

  • A MEDLINE search did not reveal prior reports of this specific interaction.

    • Implications:

    • This case highlights a potential, previously unreported drug interaction that can lead to endocrine side effects.
    • Clinicians should be aware of the possibility of gynecomastia when prescribing risperidone in combination with fluoxetine.
    • Further investigation into the mechanism of this interaction, possibly involving prolactin levels, is warranted.